Autoantibody Signature Differentiates Wilms Tumor Patients from Neuroblastoma Patients
Several studies report autoantibody signatures in cancer. The majority of these studies analyzed adult tumors and compared the seroreactivity pattern of tumor patients with the pattern in healthy controls. Here, we compared the autoimmune response in patients with neuroblastoma and patients with Wil...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Public Library of Science
2011
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241697/ |
| id |
pubmed-3241697 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-32416972011-12-22 Autoantibody Signature Differentiates Wilms Tumor Patients from Neuroblastoma Patients Schmitt, Jana Keller, Andreas Nourkami-Tutdibi, Nasenien Heisel, Sabrina Habel, Nunja Leidinger, Petra Ludwig, Nicole Gessler, Manfred Graf, Norbert Berthold, Frank Lenhof, Hans-Peter Meese, Eckart Research Article Several studies report autoantibody signatures in cancer. The majority of these studies analyzed adult tumors and compared the seroreactivity pattern of tumor patients with the pattern in healthy controls. Here, we compared the autoimmune response in patients with neuroblastoma and patients with Wilms tumor representing two different childhood tumors. We were able to differentiate untreated neuroblastoma patients from untreated Wilms tumor patients with an accuracy of 86.8%, a sensitivity of 87.0% and a specificity of 86.7%. The separation of treated neuroblastoma patients from treated Wilms tumor patients' yielded comparable results with an accuracy of 83.8%. We furthermore identified the antigens that contribute most to the differentiation between both tumor types. The analysis of these antigens revealed that neuroblastoma was considerably more immunogenic than Wilms tumor. The reported antigens have not been found to be relevant for comparative analyses between other tumors and controls. In summary, neuroblastoma appears as a highly immunogenic tumor as demonstrated by the extended number of antigens that separate this tumor from Wilms tumor. Public Library of Science 2011-12-16 /pmc/articles/PMC3241697/ /pubmed/22194956 http://dx.doi.org/10.1371/journal.pone.0028951 Text en Schmitt et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Schmitt, Jana Keller, Andreas Nourkami-Tutdibi, Nasenien Heisel, Sabrina Habel, Nunja Leidinger, Petra Ludwig, Nicole Gessler, Manfred Graf, Norbert Berthold, Frank Lenhof, Hans-Peter Meese, Eckart |
| spellingShingle |
Schmitt, Jana Keller, Andreas Nourkami-Tutdibi, Nasenien Heisel, Sabrina Habel, Nunja Leidinger, Petra Ludwig, Nicole Gessler, Manfred Graf, Norbert Berthold, Frank Lenhof, Hans-Peter Meese, Eckart Autoantibody Signature Differentiates Wilms Tumor Patients from Neuroblastoma Patients |
| author_facet |
Schmitt, Jana Keller, Andreas Nourkami-Tutdibi, Nasenien Heisel, Sabrina Habel, Nunja Leidinger, Petra Ludwig, Nicole Gessler, Manfred Graf, Norbert Berthold, Frank Lenhof, Hans-Peter Meese, Eckart |
| author_sort |
Schmitt, Jana |
| title |
Autoantibody Signature Differentiates Wilms Tumor Patients from Neuroblastoma Patients |
| title_short |
Autoantibody Signature Differentiates Wilms Tumor Patients from Neuroblastoma Patients |
| title_full |
Autoantibody Signature Differentiates Wilms Tumor Patients from Neuroblastoma Patients |
| title_fullStr |
Autoantibody Signature Differentiates Wilms Tumor Patients from Neuroblastoma Patients |
| title_full_unstemmed |
Autoantibody Signature Differentiates Wilms Tumor Patients from Neuroblastoma Patients |
| title_sort |
autoantibody signature differentiates wilms tumor patients from neuroblastoma patients |
| description |
Several studies report autoantibody signatures in cancer. The majority of these studies analyzed adult tumors and compared the seroreactivity pattern of tumor patients with the pattern in healthy controls. Here, we compared the autoimmune response in patients with neuroblastoma and patients with Wilms tumor representing two different childhood tumors. We were able to differentiate untreated neuroblastoma patients from untreated Wilms tumor patients with an accuracy of 86.8%, a sensitivity of 87.0% and a specificity of 86.7%. The separation of treated neuroblastoma patients from treated Wilms tumor patients' yielded comparable results with an accuracy of 83.8%. We furthermore identified the antigens that contribute most to the differentiation between both tumor types. The analysis of these antigens revealed that neuroblastoma was considerably more immunogenic than Wilms tumor. The reported antigens have not been found to be relevant for comparative analyses between other tumors and controls. In summary, neuroblastoma appears as a highly immunogenic tumor as demonstrated by the extended number of antigens that separate this tumor from Wilms tumor. |
| publisher |
Public Library of Science |
| publishDate |
2011 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241697/ |
| _version_ |
1611495614044962816 |